Connection
Joshua Barocas to Antiviral Agents
This is a "connection" page, showing publications Joshua Barocas has written about Antiviral Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.885 |
|
|
|
-
Barocas JA, Beiser M, Le?n C, Gaeta JM, O'Connell JJ, Linas BP. Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. JAMA Intern Med. 2017 06 01; 177(6):880-882.
Score: 0.390
-
Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study. Clin Infect Dis. 2022 08 24; 75(1):e1112-e1119.
Score: 0.140
-
Rubin EJ, Baden LR, Barocas JA, Morrissey S. Audio Interview: Addressing the Omicron Variant of SARS-CoV-2. N Engl J Med. 2022 Jan 27; 386(4):e16.
Score: 0.135
-
Barocas JA. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs. Clin Infect Dis. 2021 04 26; 72(8):1401-1403.
Score: 0.128
-
Barocas JA, Linas BP. Editorial Commentary: Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis. Clin Infect Dis. 2017 01 01; 64(1):100-101.
Score: 0.094